Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer
Expert Review of Pharmacoeconomics & Outcomes Research · 04.11.2026 · 1-11
DOI: 10.1080/14737167.2026.2760022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 04.11.2026. Verfasst von Chang Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Scientific Research Project of Heilongjiang Provincial Health Commission, Haiyan Foundation of Harbin Medical University Cancer Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: This study evaluates the cost-effectiveness of dostarlimab plus chemotherapy in contrast to chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC) from the perspective of healthcare payers in the U.S.A. RESEARCH DESIGN AND METHODS: An economic evaluation using a three‑state partitioned survival model assessed the cost-effectiveness of dostarlimab plus chemotherapy compared to chemotherapy alone. The Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) from clinical trials were digitally extracted, and the log‑normal model with network meta-analysis (NMA) was applied at the end of the trial to extrapolate long-term survival. The cost and health utility data were sourced from the published literature. RESULTS: The anticipated expenditure for dostarlimab plus chemotherapy therapy exceeded the cost for chemotherapy alone therapy (366,887.33 USD vs 102,503.32 USD). The estimated utility was also greater compared to that of chemotherapy alone treatment (3.74 QALYs vs 1.90 QALYs). The ICER was 143,856.30 USD/QALY. CONCLUSIONS: Dostarlimab plus chemotherapy was cost-effective compared to chemotherapy alone as a first-line treatment for advanced or metastatic NSCLC patients at the WTP threshold of 150,000 USD/QALY in the U.S.A.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.
Förderung
- Scientific Research Project of Heilongjiang Provincial Health Commission
- Haiyan Foundation of Harbin Medical University Cancer Hospital
Zitieren
APA
Cheng, C., & Liu, T. (2026). Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research, 1-11. https://doi.org/10.1080/14737167.2026.2760022
Vancouver
Cheng C, Liu T. Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-11. doi:10.1080/14737167.2026.2760022
BibTeX
@article{Cheng2026,
author = {Cheng, Chang and Liu, Tong},
title = {Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
pages = {1--11},
doi = {10.1080/14737167.2026.2760022}
}
EUVIMED